Treatment(s) already received-Hormonal therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Hormonal therapy Posts on Medivizor

Searching for patients with metastatic castration resistant prostate cancer to test a targeted therapy option

Posted by on Jun 24, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of trametinib (Mekinist) in patients with metastatic castration-resistant prostate cancer (mCRPC; prostate cancer which has spread from its original place to another area in the body and keeps growing even when the amount of testosterone in the body...

Read More

Evaluating a radionuclide treatment for metastatic castration-resistant prostate cancer

Posted by on Mar 26, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness of a radionuclide (RN), [¹??Lu]-PSMA-617, to treat metastatic castration-resistant prostate cancer (mCRPC) that has worsened after standard treatments. They found that this treatment was safe and effective for these patients. Some background Prostate cancer (PC) affects the...

Read More

The use of curcumin in prostate cancer

Posted by on Feb 5, 2019 in Prostate cancer | 0 comments

In a nutshell This study looked at the effect of curcumin on prostate cancer. It concluded that curcumin taken for 6 months was safe but did not reduce the need for hormone suppression therapy.  Some background Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate cancer can be treated by medication,...

Read More

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Posted by on Aug 21, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...

Read More

Does age matter? Enzalutamide or bicalutamide for mestastatic castration-resistant prostate cancer patients of different ages

Posted by on Feb 12, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...

Read More

Looking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone

Posted by on Dec 5, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...

Read More

Guidelines for the use of hormone therapy in hormone receptor-positive patients with metastatic breast cancer.

Posted by on Aug 1, 2017 in Breast cancer | 0 comments

In a nutshell This report aimed to develop recommendations for endocrine therapy in women with hormone receptor-positive metastatic breast cancer. Some background Endocrine therapy, also known as hormone therapy (HT) is used to treat hormone receptor (HR) positive metastatic breast cancer (MBC). HR positive MBC depends on the hormones estrogen or...

Read More